APA (7th ed.) Citation

J, H., D, W., Y, Z., Y, Z., T, T., W, L., . . . Y, W. (2026). The Consideration of Appropriate Surrogate Endpoint in Premarket Clinical Trials of Drug-Coated Balloon Catheter for the Treatment of Femoropopliteal Artery Stenosis. Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists, 33(3), 1370. https://doi.org/10.1177/15266028241300861

Chicago Style (17th ed.) Citation

J, Hao, Wang D, Zhao Y, Zhu Y, Tinley T, Liu W, Li W, Wang C, and Wang Y. "The Consideration of Appropriate Surrogate Endpoint in Premarket Clinical Trials of Drug-Coated Balloon Catheter for the Treatment of Femoropopliteal Artery Stenosis." Journal of Endovascular Therapy : An Official Journal of the International Society of Endovascular Specialists 33, no. 3 (2026): 1370. https://doi.org/10.1177/15266028241300861.

MLA (9th ed.) Citation

J, Hao, et al. "The Consideration of Appropriate Surrogate Endpoint in Premarket Clinical Trials of Drug-Coated Balloon Catheter for the Treatment of Femoropopliteal Artery Stenosis." Journal of Endovascular Therapy : An Official Journal of the International Society of Endovascular Specialists, vol. 33, no. 3, 2026, p. 1370, https://doi.org/10.1177/15266028241300861.